Abstract Number: 1027 • 2017 ACR/ARHP Annual Meeting
Quantification of Leukocytes’ Secretome to Guide Diagnosis and Treatment Options in Patients with Suspected Chronic Auto-Inflammatory Syndromes
Background/Purpose: Auto-inflammatory syndromes are inherited conditions characterized by recurrent inflammation (fever, abdominal pain, dermatitis, arthritis). Diagnosis and treatments are challenging as detection rate of mutations…Abstract Number: 1028 • 2017 ACR/ARHP Annual Meeting
Association of a Non-Synonymous, Loss-of-Function, Variant in NOD2 with Reduced Tissue Damage in ACPA +Ve RA
Background/Purpose: The functional capacity of individuals with rheumatoid arthritis (RA) is related to the severity of damage to bone and cartilage within joints. This is…Abstract Number: 1029 • 2017 ACR/ARHP Annual Meeting
What to Measure after Arthroplasty? Confirmation of a Core Domain Set
Background/Purpose: The Outcomes Measures in Rheumatology Trials (OMERACT) TJR Working Group has proposed six core domains that would constitute a standardized measurement set that can…Abstract Number: 1030 • 2017 ACR/ARHP Annual Meeting
Healthcare Service Utilization and Costs of Certolizumab Pegol Versus Infliximab Treatment in Patients with Rheumatoid Arthritis
Background/Purpose: Prior retrospective claims analyses examining rheumatoid arthritis (RA) treatment costs have shown infliximab (IFX) to be costlier than certolizumab pegol (CZP) across all sites…Abstract Number: 1031 • 2017 ACR/ARHP Annual Meeting
Developing a Multi-Phase Claims-Based Algorithm to Facilitate the Study of Drug Exposure during Pregnancy
Background/Purpose: The use of antirheumatic medications during pregnancy may lead to birth defects or other complications. Safety studies are critical, with registries being common but…Abstract Number: 1032 • 2017 ACR/ARHP Annual Meeting
Trends in Hospitalizations Following Heart Failure Diagnosis in Rheumatoid Arthritis
Background/Purpose: The rising prevalence of heart failure (HF) in the general population and associated increased hospitalization costs is a major public health problem. There is…Abstract Number: 1033 • 2017 ACR/ARHP Annual Meeting
Burden of Illness in Patients with RA and Anti-Cyclic Citrullinated Peptide Positivity
Background/Purpose: RA is often treated with a biologic DMARD (bDMARD), such as abatacept (ABA) or a TNF inhibitor (TNFi). Real-world data on how economic outcomes…Abstract Number: 1034 • 2017 ACR/ARHP Annual Meeting
Presence of Anti-Cyclic Citrullinated Peptide Antibodies Is Associated with Better Treatment Response to Abatacept but Not to TNF Inhibitors in Patients with RA: A Meta-Analysis
Background/Purpose: The association between anti-citrullinated protein antibody (ACPA) status and erosions, as well as response to TNF inhibitor (TNFi) treatment, has been explored.1,2 Results based…Abstract Number: 1035 • 2017 ACR/ARHP Annual Meeting
Risk of Hospitalization Among RA Patients with Multiple Autoimmune Co-Morbidities Differs By DMARD Treatment
Background/Purpose: Patients (pts) with autoimmune (AI) disorders are at higher risk of developing another AI disorder; co-occurrence of some AI conditions is reported more frequently…Abstract Number: 1036 • 2017 ACR/ARHP Annual Meeting
Blood Glucose Changes Surrounding Initiation of Tumor-Necrosis Factor Inhibitors and Conventional Disease-Modifying Anti-Rheumatic Drugs in Veterans with Rheumatoid Arthritis
Background/Purpose: There is evidence linking activation of the innate immune system and insulin resistance. Perturbations in glucose homeostasis upon initiation of tumor-necrosis factor inhibitors (TNFis)…Abstract Number: 1037 • 2017 ACR/ARHP Annual Meeting
Biosimilar Knowledge Among US Rheumatologists – a Survey
Background/Purpose: Four biosimilar tumor necrosis factor α (TNFα) inhibitors have been approved by the FDA in the United States as of April 2017. This survey…Abstract Number: 1038 • 2017 ACR/ARHP Annual Meeting
Impact of Patient Support Program Utilization on Patient Activation Measure Scores Among Patients with Rheumatoid Arthritis
Background/Purpose : AbbVie’s Patient (pt) Support Program (PSP) is offered to pts who are prescribed adalimumab (ADA) for their Rheumatoid arthritis (RA). The purpose of…Abstract Number: 1039 • 2017 ACR/ARHP Annual Meeting
Influences for Therapeutic Changes in Rheumatoid Arthritis Patients from the Veterans Affairs Rheumatology Arthritis Registry Who Have Moderate to High Disease Activity
Background/Purpose: Current guidelines encourage the measurement of rheumatoid arthritis (RA) disease activity to achieve a low disease state (treat-to-target). Many RA patients with documented moderate…Abstract Number: 1040 • 2017 ACR/ARHP Annual Meeting
Perceptions of US Community Rheumatologists on Biosimilars
Background/Purpose: Biosimilars contain a highly similar version of the active substance of an already approved biologic or “reference product.”1 Regulatory agencies mandate that safety, efficacy,…Abstract Number: 1041 • 2017 ACR/ARHP Annual Meeting
Real-World Utilization of Biosimilars for Management of Rheumatoid Arthritis (RA) in the US
Background/Purpose: A biosimilar product is a biological product highly similar to another FDA-approved biological product, reference product, and has no clinically meaningful differences in safety…
ACR Meeting Abstracts